HRMY Q2 2024 Earnings — Harmony Biosciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

HRMYHarmony Biosciences Holdings, Inc.

$2B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$173M+28.8% YoY

Gross Profit

$141M81.4% margin

Operating Income

$21M12.4% margin

Net Income

$12M6.7% margin

EPS (Diluted)

$0.20

QoQ Revenue Growth

+11.8%

Cash Flow

Operating Cash Flow

$43M

Free Cash Flow

$42M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$858M

Total Liabilities

$320M

Stockholders' Equity

$539M

Cash & Equivalents

$317M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$173M	$134M	+28.8%
Gross Profit	$141M	$109M	+28.8%
Operating Income	$21M	$47M	-54.5%
Net Income	$12M	$34M	-66.2%